Silverarc Capital Management, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 12, 2026), Silverarc Capital Management, LLC reported 63 stock positions worth $691.1 million. Its top holding was Abivax SA-ADR (ABVX) at 8.2% of the portfolio, followed by Cogent Biosciences (COGT, 6.4%) and Urogen Pharma (URGN, 5.9%). Compared with Q3 2025, it opened 18 new positions, sold out of 27, added to 18 and reduced 26. The biggest buy was Celcuity (CELC, shares +323%) and the biggest sale an exit from Avidity Biosciences (RNAM).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001816307
- Portfolio Value
- $691.1M (Q4 2025)
- SEC Filing
- 0001420506-26-000321 ↗ filed Feb 12, 2026
Holdings Value
Holdings 63 stocks · $691.1M
| ABVX Abivax SA-ADR | 8.24% | 422,193 | $56.9M | Reduce -21.8% |
| COGT Cogent Biosciences Inc. | 6.40% | 1,245,254 | $44.2M | Add +52.8% |
| URGN Urogen Pharma Ltd. | 5.89% | 1,738,821 | $40.7M | Add +10.2% |
| KALV Kalvista Pharmaceuticals Inc. | 5.67% | 2,427,118 | $39.2M | Add +78.0% |
| CELC Celcuity Inc. | 5.41% | 375,132 | $37.4M | Add +323.0% |
| NUVL Nuvalent Inc. Class A | 4.53% | 311,430 | $31.3M | Reduce -16.4% |
| DNTH Dianthus Therapeutics Inc. | 4.47% | 750,136 | $30.9M | Add +11.1% |
| KOD Kodiak Sciences Inc. | 4.14% | 1,023,122 | $28.6M | Add +2.3% |
| PRAX Praxis Precision Medicines I | 3.52% | 82,465 | $24.3M | Add +61.0% |
| IMNM Immunome Inc. | 3.50% | 1,126,210 | $24.2M | New |
| GUTS Fractyl Health Inc. | 3.13% | 9,840,041 | $21.6M | Reduce -7.2% |
| GLUE Monte Rosa Therapeutics Inc. | 2.33% | 1,029,066 | $16.1M | Add +48.1% |
| VCYT Veracyte Inc. | 2.18% | 357,558 | $15.1M | Add +51.6% |
| CGON CG Oncology Inc. | 2.17% | 361,158 | $15.0M | Reduce -43.4% |
| RYTM Rhythm Pharmaceuticals Inc. | 2.11% | 135,950 | $14.6M | Reduce -63.3% |
| SNDX Syndax Pharmaceuticals Inc. | 1.95% | 642,899 | $13.5M | Add +38.6% |
| BIIB Biogen Inc. | 1.92% | 75,412 | $13.3M | Reduce -6.2% |
| INSM Insmed Inc. | 1.79% | 71,256 | $12.4M | Reduce -65.5% |
| CNTA Centessa Pharmaceuticals Ltd. | 1.66% | 458,203 | $11.5M | Add +224.4% |
| VRDN Viridian Therapeutics Inc. | 1.57% | 348,569 | $10.8M | Add +34.3% |
| ASND Ascendis Pharma A/S | 1.52% | 49,228 | $10.5M | Reduce -8.1% |
| PFE Pfizer Inc. | 1.51% | 419,134 | $10.4M | New |
| BNTC Benitec Biopharma Inc. | 1.43% | 731,717 | $9.9M | Add +164.9% |
| AVTX Avalo Therapeutics Inc. | 1.38% | 524,436 | $9.5M | Reduce -27.3% |
| GH Guardant Health Inc. | 1.36% | 91,914 | $9.4M | New |
| ORIC Oric Pharmaceuticals Inc. | 1.32% | 1,116,604 | $9.1M | Reduce -42.7% |
| PCVX Vaxcyte Inc. | 0.99% | 148,787 | $6.9M | Reduce -52.7% |
| TRVI Trevi Therapeutics Inc. | 0.98% | 541,240 | $6.8M | Reduce -8.1% |
| GOSS Gossamer Bio Inc. | 0.96% | 2,135,722 | $6.6M | Reduce -55.3% |
| SYRE Spyre Therapeutics Inc. | 0.89% | 187,737 | $6.2M | New |
| LXEO Lexeo Therapeutics Inc. | 0.89% | 617,608 | $6.1M | Reduce -20.7% |
| AMLX Amylyx Pharmaceuticals Inc. | 0.88% | 506,242 | $6.1M | Reduce -27.7% |
| CERS Cerus Corp. | 0.84% | 2,814,383 | $5.8M | Add +3.6% |
| CMPX Compass Therapeutics Inc. | 0.82% | 1,051,343 | $5.6M | Reduce -62.9% |
| SLNO Soleno Therapeutics Inc. | 0.79% | 117,485 | $5.4M | New |
| CGEN Compugen Ltd. | 0.77% | 3,479,805 | $5.3M | Add +5.1% |
| CLDX Celldex Therapeutics Inc. | 0.75% | 191,074 | $5.2M | Reduce -45.2% |
| OLMA Olema Pharmaceuticals Inc. | 0.75% | 206,280 | $5.2M | Reduce -77.9% |
| ERAS Erasca Inc. | 0.71% | 1,317,584 | $4.9M | Reduce -3.7% |
| FULC Fulcrum Therapeutics Inc. | 0.65% | 394,650 | $4.5M | New |
| AARD Aardvark Therapeutics Inc. | 0.58% | 303,939 | $4.0M | Reduce -1.0% |
| CCCC C4 Therapeutics Inc. | 0.55% | 1,994,224 | $3.8M | Add +5.1% |
| SRZN Surrozen Inc. | 0.51% | 157,323 | $3.6M | New |
| CTNM Contineum Therapeutics Inc. Class A | 0.51% | 307,540 | $3.5M | Add +85.1% |
| MLYS Mineralys Therapeutics Inc. | 0.50% | 94,983 | $3.4M | Add +18.7% |
| RLAY Relay Therapeutics Inc. | 0.49% | 398,167 | $3.4M | New |
| ABEO Abeona Therapeutics Inc. | 0.48% | 627,738 | $3.3M | Reduce -36.9% |
| TELA Tela Bio Inc. | 0.45% | 2,647,512 | $3.1M | Reduce -4.9% |
| QURE Uniqure NV | 0.44% | 126,047 | $3.0M | Reduce -72.3% |
| TARS Tarsus Pharmaceuticals Inc. | 0.43% | 36,124 | $3.0M | New |
| KYMR Kymera Therapeutics Inc. | 0.39% | 34,589 | $2.7M | New |
| NXTC Nextcure Inc. | 0.36% | 176,057 | $2.5M | New |
| ELUT Elutia Inc. | 0.28% | 2,751,314 | $1.9M | Reduce -3.5% |
| SION Sionna Therapeutics Inc. | 0.25% | 41,460 | $1.7M | Reduce -61.9% |
| CTMX Cytomx Therapeutics Inc. | 0.24% | 385,974 | $1.6M | New |
| XFOR X4 Pharmaceuticals Inc. | 0.21% | 357,387 | $1.4M | New |
| EWTX Edgewise Therapeutics Inc. | 0.15% | 42,052 | $1.0M | New |
| RADX Radiopharm Theranostics Ltd. | 0.14% | 187,406 | $978K | No change |
| FDMT 4D Molecular Therapeutics Inc. | 0.11% | 100,000 | $750K | New |
| ADGM Adagio Medical Holdings Inc. | 0.08% | 515,384 | $536K | New |
| RAPP Rapport Therapeutics Inc. | 0.04% | 9,659 | $293K | Reduce -95.3% |
| PALI Palisade Bio Inc. | 0.03% | 102,108 | $240K | New |
| IBIO Ibio Inc. | 0.03% | 106,000 | $205K | New |
Options reported separately and not counted above: UNIQURE NV calls ($17.2M), KALVISTA PHARMACEUTICALS INC calls ($4.7M), FULCRUM THERAPEUTICS INC calls ($4.4M), ULTRAGENYX PHARMACEUTICAL IN calls ($2.5M).
Other holdings (1): bonds, preferreds, convertibles and warrants · $3K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 104,828 | $3K | No change |
Total filed on the 13F, all lines: $691.1M.
Portfolio Sells Q3 2025 → Q4 2025
| RNAM Avidity Biosciences Inc. | Sold out | 0.00% | −5.33 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −4.42 |
| QURE Uniqure NV | Reduce -72.3% | 0.44% | −3.41 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -63.3% | 2.11% | −3.30 |
| CDTX Cidara Therapeutics Inc. | Sold out | 0.00% | −3.06 |
| INSM Insmed Inc. | Reduce -65.5% | 1.79% | −2.51 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -42.7% | 1.32% | −2.06 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −1.68 |
| CGON CG Oncology Inc. | Reduce -43.4% | 2.17% | −1.55 |
| VSTM Verastem Inc. | Sold out | 0.00% | −1.33 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −1.26 |
| GOSS Gossamer Bio Inc. | Reduce -55.3% | 0.96% | −0.86 |
| RAPP Rapport Therapeutics Inc. | Reduce -95.3% | 0.04% | −0.83 |
| ALKS Alkermes PLC | Sold out | 0.00% | −0.78 |
| BBOT Bridgebio Oncology Therapeut | Sold out | 0.00% | −0.77 |
| PHVS Pharvaris NV | Sold out | 0.00% | −0.66 |
| PCVX Vaxcyte Inc. | Reduce -52.7% | 0.99% | −0.65 |
| CMPX Compass Therapeutics Inc. | Reduce -62.9% | 0.82% | −0.62 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -77.9% | 0.75% | −0.58 |
| BCAX Bicara Therapeutics Inc. | Sold out | 0.00% | −0.57 |
| CLDX Celldex Therapeutics Inc. | Reduce -45.2% | 0.75% | −0.56 |
| KNSA Kiniksa Pharmaceuticals Inte | Sold out | 0.00% | −0.50 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -27.7% | 0.88% | −0.49 |
| EYPT Eyepoint Inc. | Sold out | 0.00% | −0.48 |
| ZURA Zura Bio Ltd. | Sold out | 0.00% | −0.45 |
| DCTH Delcath Systems Inc. | Sold out | 0.00% | −0.32 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −0.30 |
| CAMP CAMP4 Therapeutics Corp. | Sold out | 0.00% | −0.28 |
| ABEO Abeona Therapeutics Inc. | Reduce -36.9% | 0.48% | −0.28 |
| SION Sionna Therapeutics Inc. | Reduce -61.9% | 0.25% | −0.22 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −0.18 |
| LBRX LB Pharmaceuticals Inc. | Sold out | 0.00% | −0.16 |
| MRSN Mersana Therapeutics Inc. | Sold out | 0.00% | −0.15 |
| TELA Tela Bio Inc. | Reduce -4.9% | 0.45% | −0.15 |
| NUVL Nuvalent Inc. Class A | Reduce -16.4% | 4.53% | −0.13 |
| IMVT Immunovant Inc. | Sold out | 0.00% | −0.12 |
| ELUT Elutia Inc. | Reduce -3.5% | 0.28% | −0.09 |
| MODULAR MED INC | Sold out | 0.00% | −0.06 |
| BDSX Biodesix Inc. | Sold out | 0.00% | −0.05 |
| MBX MBX Biosciences Inc. | Sold out | 0.00% | −0.04 |
| ELVN Enliven Therapeutics Inc. | Sold out | 0.00% | −0.03 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −0.03 |
| ASND Ascendis Pharma A/S | Reduce -8.1% | 1.52% | −0.02 |
| AARD Aardvark Therapeutics Inc. | Reduce -1.0% | 0.58% | −0.01 |
| ARCT Arcturus Therapeutics Holdin | Sold out | 0.00% | −0.01 |
| NKTR Nektar Therapeutics | Sold out | 0.00% | −0.00 |
| AVTX Avalo Therapeutics Inc. | Reduce -27.3% | 1.38% | +0.05 |
| LXEO Lexeo Therapeutics Inc. | Reduce -20.7% | 0.89% | +0.14 |
| TRVI Trevi Therapeutics Inc. | Reduce -8.1% | 0.98% | +0.20 |
| ERAS Erasca Inc. | Reduce -3.7% | 0.71% | +0.28 |
Portfolio Buys Q3 2025 → Q4 2025
| CELC Celcuity Inc. | Add +323.0% | 5.41% | +4.78 |
| COGT Cogent Biosciences Inc. | Add +52.8% | 6.40% | +4.71 |
| IMNM Immunome Inc. | New | 3.50% | +3.50 |
| KALV Kalvista Pharmaceuticals Inc. | Add +78.0% | 5.67% | +3.27 |
| PRAX Praxis Precision Medicines I | Add +61.0% | 3.52% | +3.12 |
| KOD Kodiak Sciences Inc. | Add +2.3% | 4.14% | +1.77 |
| GLUE Monte Rosa Therapeutics Inc. | Add +48.1% | 2.33% | +1.59 |
| PFE Pfizer Inc. | New | 1.51% | +1.51 |
| GH Guardant Health Inc. | New | 1.36% | +1.36 |
| URGN Urogen Pharma Ltd. | Add +10.2% | 5.89% | +1.34 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +224.4% | 1.66% | +1.16 |
| VCYT Veracyte Inc. | Add +51.6% | 2.18% | +1.01 |
| SNDX Syndax Pharmaceuticals Inc. | Add +38.6% | 1.95% | +0.92 |
| SYRE Spyre Therapeutics Inc. | New | 0.89% | +0.89 |
| BNTC Benitec Biopharma Inc. | Add +164.9% | 1.43% | +0.86 |
| SLNO Soleno Therapeutics Inc. | New | 0.79% | +0.79 |
| VRDN Viridian Therapeutics Inc. | Add +34.3% | 1.57% | +0.76 |
| FULC Fulcrum Therapeutics Inc. | New | 0.65% | +0.65 |
| DNTH Dianthus Therapeutics Inc. | Add +11.1% | 4.47% | +0.63 |
| SRZN Surrozen Inc. | New | 0.51% | +0.51 |
| RLAY Relay Therapeutics Inc. | New | 0.49% | +0.49 |
| TARS Tarsus Pharmaceuticals Inc. | New | 0.43% | +0.43 |
| KYMR Kymera Therapeutics Inc. | New | 0.39% | +0.39 |
| NXTC Nextcure Inc. | New | 0.36% | +0.36 |
| CTMX Cytomx Therapeutics Inc. | New | 0.24% | +0.24 |
| CTNM Contineum Therapeutics Inc. Class A | Add +85.1% | 0.51% | +0.23 |
| CERS Cerus Corp. | Add +3.6% | 0.84% | +0.21 |
| XFOR X4 Pharmaceuticals Inc. | New | 0.21% | +0.21 |
| EWTX Edgewise Therapeutics Inc. | New | 0.15% | +0.15 |
| FDMT 4D Molecular Therapeutics Inc. | New | 0.11% | +0.11 |
| ADGM Adagio Medical Holdings Inc. | New | 0.08% | +0.08 |
| CGEN Compugen Ltd. | Add +5.1% | 0.77% | +0.07 |
| MLYS Mineralys Therapeutics Inc. | Add +18.7% | 0.50% | +0.06 |
| PALI Palisade Bio Inc. | New | 0.03% | +0.03 |
| IBIO Ibio Inc. | New | 0.03% | +0.03 |
| CCCC C4 Therapeutics Inc. | Add +5.1% | 0.55% | −0.06 |
Options Activity Q3 2025 → Q4 2025
| UNITED THERAPEUTICS CORP DEL | put | Sold out | 59,900 | $25.1Mbefore exit |
| UNIQURE NV | call | New | 720,800 | $17.2M |
| COGENT BIOSCIENCES INC | call | Sold out | 360,000 | $5.2Mbefore exit |
| KALVISTA PHARMACEUTICALS INC | call | New | 290,600 | $4.7M |
| FULCRUM THERAPEUTICS INC | call | New | 391,900 | $4.4M |
| ULTRAGENYX PHARMACEUTICAL IN | call | Reduce -79.2% | 110,000 | $2.5M |
| CAPRICOR THERAPEUTICS INC | put | Sold out | 144,700 | $1.0Mbefore exit |
| ATYR PHARMA INC | put | Sold out | 1,250,000 | $901Kbefore exit |
| ARCTURUS THERAPEUTICS HLDGS | put | Sold out | 42,000 | $774Kbefore exit |
| SYNDAX PHARMACEUTICALS INC | call | Sold out | 50,000 | $770Kbefore exit |
| ULTRAGENYX PHARMACEUTICAL IN | put | Sold out | 25,000 | $752Kbefore exit |
| MOONLAKE IMMUNOTHERAPEUTICS | call | Sold out | 65,000 | $466Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 64 | $898.5M | ASND, CELC, COGT, URGN, IMNM |
| Q1 2026 | 66 | $848.6M | KALV, DNTH, COGT, CELC, IMNM |
| Q4 2025 | 63 | $691.1M | ABVX, COGT, URGN, KALV, CELC |
| Q3 2025 | 72 | $690.7M | ABVX, RYTM, RNAM, NUVL, URGN |
| Q2 2025 | 56 | $488.6M | MRUS, AKRO, VRNA, URGN, RYTM |
| Q1 2025 | 66 | $478.6M | VRNA, MRUS, NUVL, AKRO, INSM |
| Q4 2024 | 57 | $447.2M | NUVL, MRUS, INSM, VRNA, AKRO |
| Q3 2024 | 67 | $443.7M | NUVL, MRUS, INSM, RNAM, ERAS |
| Q2 2024 | 65 | $405.1M | MRUS, NUVL, RNAM, URGN, ERAS |
| Q1 2024 | 72 | $356.6M | MRUS, SLDB, MORF, ORIC, MERSANA THERAPEUTICS INC |